Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma

Gynecologic Oncology

Volumn 119, Issue 2, 2010, Pages 325-331

  Scheil Bertram, Stefanie ^a   Tylus Schaaf, Patricia ^a   Du Bois, Andreas ^a   Harter, Philipp ^a   Oppitz, Matthias ^a   Ewald Riegler, Nina ^a   Fisseler Eckhoff, Annette ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

ERCC1; Ovarian carcinoma; Survival

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; PLATINUM DERIVATIVE; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CORRELATION ANALYSIS; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OVARY ADENOCARCINOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SEROUS OVARY ADENOCARCINOMA; TISSUE MICROARRAY; AGE; BIOSYNTHESIS; CYSTADENOCARCINOMA; ENZYMOLOGY; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PREDICTIVE VALUE; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CYSTADENOCARCINOMA, SEROUS; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES;

EID: 77957751885     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.07.018     Document Type: Article

References (32)

1. K.R. Lee, F.A. Tavassoli, and J. Prat Surface epithelial-stromal tumours World Health Organization classification of tumours. Pathology & Genetics Tumours of the breast and female genital organs 2003 IARC Press Lyon 117 145
2. P. Harter, and A. du Bois The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence Curr Opin Oncol 17 2005 505 514
3. P. Wimberger, N. Lehmann, and R. Kimmig Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR) Gynecol Oncol 106 1 2007 69 74
4. W.E. Winter III, G.L. Maxwell, and C. Tian Gynecologic Oncology Group Study. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 24 2007 3621 3627
5. Giovanni D. Aletti, and William A. Cliby Primary cytoreduction in advanced ovarian cancer: 'Biologic and Surgical Aggressiveness'. www.cancernetwork.com Oncology 22 9 2008
6. A. du Bois, A. Reuss, and E. Pujade-Lauraine Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO) Cancer 115 2009 1234 1244
7. M. Van Duin, J. de Wit, and H. Odijk Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10 Cell 44 1986 913 923
8. M. Dabholkar, F. Bostick Bruton, and C. Weber ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients J Natl Cancer Inst 84 1992 1512 1517
9. M. Dabholkar, J.A. Vionnet, and F. Bostick Bruton Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy J Clin Invest 94 2 1994 703 708
10. C. Walsh, S. Ogawa, and H. Karahashi ERCC is a novel biomarker of ovarian cancer prognosis J Clin Oncol 26 2008 2952 2958
11. P. Ceppi, M. Volante, and S. Novello ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non small cell lung cancer treated with cisplatin and gemcitabine Ann Oncol 17 2006 1818 1825
12. E. Reed, J.J. Yu, and A. Davies Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer Clin Cancer Res 9 2003 5299 5305
13. M. Selvakumaran, D. Pisarcik, and R. Bao Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines Cancer Res 63 2003 1311 1316
14. J. Weberpals, K. Garbuio, and A. O'Brien The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer Int J Cancer 124 2009 806 815
15. J.J. Yu, K. Thronton, and Y. Guo An ERCC1 splicing variant involving the 5′-UTR of the mRNA may have a transcription modulatory function Oncogene 20 2001 7694 7698
16. Q. Li, K. Gardnder, and L. Zhang Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells J Biol Chem 273 36 1998 23419 23425
17. K. Lin, D. Ze, and X. Xie Protein expression levels of excision repair cross-complementation group 1 and xeroderma pigmentosum D correlate with response to platinum-based chemotherapy in the patients with advanced epithelial ovarian cancer Int J Gynecol Cancer 18 5 2008 1007 1012
18. K.A. Olaussen, A. Dunant, and P. Fouret DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med 355 2006 983 991
19. K.D. Steffensen, M. Waldenstroms, and U. Jeppesen Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer Int J Gynecol Cancer 18 4 2008 702 710
20. K.D. Steffensen, M. Waldstrøm, and A. Jakobsen The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer Int J Gynecol Cancer 19 5 2009 820 825
21. S. Stadlmann, S. Dirnhofer, and U. Güth ERCC1 immunoexpression does not predict platinum resistance in ovarian cancer J Gynecol Oncol. 108 1 2008 252 253
22. K.A. Olaussen, and J.C. Soria Validation of ERCC1-XPF immunodetection - letter Cancer Res 70 9 2010 3851 3852
23. S. Stadlmann, S. Dirnhofer, U. Güth, S. Stadlmann, S. Dirnhofer, and U. Güth ERCC1-immunoexpression does not predict platinum-resistance in ovarian cancer Pathologe Supplement 1 2008 98
24. S. Kang, W. Ju, and J.W. Kim Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer Exp Mol Med 38 3 2006 320 324
25. S. Smith, D. Su, and I.A. Rigault de la Longrais ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy J Clin Oncol 25 33 2007 5172 5179
26. T.C. Krivak, K.M. Darcy, and C. Tian Gynecologic Oncology Group Phase III Trial. Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer J Clin Oncol 26 21 2008 3598 3606
27. J.J. Yu, K. Thornton, Y. Guo, and H. Kotz An ERCC1 splicing variant involving the 5′-UTR of the mRNA may have a transcriptional modulatory function Oncogene 20 52 2001 7694 7698
28. R. Vang, IeM Shih, and R. Salani Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data Am J Surg Pathol 32 11 2008 1667 1674
29. R.J. Kurman, and I.M. Shih Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications Int J Gynecol Pathol 27 2 2008 151 160
30. H. Katabuchi, H. Tasshiro, and K.R. Cho Micropapillary serous carcinoma of the ovary: an immunohistochemical and mutational analysis of p53 Int J Gynecol Pathol 17 1998 54 60
31. P.C. Cheng, J.A. Gosewehr, and T.M. Kim Potential role of the inactivated X chromosome in ovarian epithelial tumor developement J Natl Cancer Inst 88 1996 510 518
32. H. Song, S.J. Ramus, and D. Shadforth Common variants in RB1 gene and risk of invasive ovarian cancer Cancer Res 66 20 2006 10220 10226 (Pubitemid 44672078)